HIV can harm the brain, leading to memory and thinking issues, and cannot be removed once it enters. The virus targets helper T cells, part of the immune system, which identify and react to pathogens, including those in the brain. By reducing helper T cells, HIV weakens immunity, increasing the risk of AIDS.
Antiviral drugs can manage HIV but struggle to reach the brain and spinal cord. Research labs, including one at UC Davis, are studying how helper T cells function to develop vaccines and treatments. However, when these cells carry HIV into the brain, the virus hides and causes ongoing inflammation, speeding up brain aging.
Currently, no treatment can remove HIV from the brain. Researchers are exploring ways to reduce inflammation caused by the virus. Collaborating with labs at UC Davis and the University of Pittsburgh, one study tested a new therapy aimed at lowering brain inflammation. Instead, it unexpectedly increased virus levels.
This study looked at proteins called integrins, which help immune cells move within the body. Blocking integrins might reduce inflammation by stopping HIV from reaching the brain. The team used a drug for multiple sclerosis on monkeys with SIV, an HIV-like virus. However, blocking one integrin increased viral presence in the brain.
Researchers noticed the treatment reduced essential killer T cells, not helper T cells, allowing the virus to thrive. This finding suggests treatments targeting specific immune cells may better prevent brain damage from HIV. Continued research could lead to improved therapies, which is crucial as HIV remains a major global health challenge, affecting millions worldwide without sufficient treatment access.
Test Your Understanding
How much do you know?





